Skip to content
Capital Law Firm
Capital Law Firm Pakistan Chambers
Insights & Publications

DRAP Regulations & Pharmaceutical IP: Protecting Innovation in Pakistan

Author: Sajid Ilyas Bhatti

Back to Insights
Medical and pharmaceutical research documents

1. DRAP’s Regulatory Mandate

The Drug Regulatory Authority of Pakistan (DRAP) was established under the DRAP Act 2012 as the single federal authority for pharmaceutical, biological, and medical device regulation. DRAP oversees product registration, manufacturing facility licensing, and market authorization — processes that directly intersect with intellectual property rights.

2. Patent Linkage and Market Authorization

Pakistan currently does not implement formal patent linkage between DRAP registration and IPO-P patent databases. This means generic manufacturers can obtain DRAP registration for a product that is still under a valid patent, shifting the enforcement burden entirely to the patent holder. Key implications:

  • Innovator companies must file for patent term extension before expiry to maintain exclusivity.
  • Data exclusivity protections for clinical trial data exist for 5 years under DRAP guidelines.
  • Counterfeit and substandard medicines enforcement requires coordinated action between DRAP, FIA, and IPO-P.

3. Strategy for Pharmaceutical Market Entry

A robust market entry strategy requires filing patents with IPO-P early, coordinating DRAP registration timelines with patent lifecycles, and engaging specialized IP counsel familiar with both DRAP administrative procedures and civil court enforcement mechanisms for patent infringement.

Article Info

Author: Sajid Ilyas Bhatti
Published: May 30, 2026
Read Time: 7 min read

Legal Representation

Schedule a confidential consultation to review your legal matter or compliance requirements.

Contact Sajid Ilyas Bhatti